Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lower pps on bigger volume: are we entering a downtrend? Or selling of Pope? Or just an off-day?
As always time will tell.
Catching a falling knife?
or
That's their advantage, they have the power, JGBO had to seduce them to cooperate so they gave a discount on the shareprice.
On the other hand isn't it a good sign that Pope accepts these 82,500 shares instead of $660,000? They would prefer the cash if they thought the shares were crappy I guess...
I admit I find this situation not so funny. The issue exists already a few months now, why haven't they been able to find a solution?
Secondly I think we won't get any clear answers soon. Remember the list with questions/issues we all contributed too, I mailed it to Crocker and Elsa. Most of the questions never got answered. I'm afraid it is not going to be different this time.
Well let's not get ntoo negative... fundamentals are good. This shold be merely a bunp in the road...
Keeping my fingers crossed.
Well the answer can be found in looking at other chinese companies whose shares trade at OTCBB or AMEX or Nasdaq. Have they been able to move money from PRC to US if necessary? If so than I should think JGBO should be able to work that out too. For sure they are not the only ones who have had this problem. If nobody has been able to work out a solution than I think our future looks less attractive: dilution?
As before time will tell. But expect no answer before the Q4 results... patience again
82,500 extra share on approximately 10,5 million outstanding = 0,7%
@ericteg: they gave Pope 82,500 shares instead of paying $660,000 interest which was du bu couldn't be payed because of the "money transfer problem".
Your other concerns I can't answer (yet) First have to read the filing a couple of more times
I will settle for that too. Nice volume, nice steady rise. An occasional jump to +14$ would be nice for a day or two. Just to get used too...
Don't bother them too much.
I guess they are working very hard on the uplisting ...
Magical 12 or what ?!
Some day soon we will blast right trough...
Nice volume again.
At least were back at level $11. Let's keep that up until we get news or numbers. Then we can climb further: $20-30-40 FY 2011-2012 ?
@ericteg and wiedsche: that is a nice summary of what Glen is saying in his article. But I don't think Glen is a professional analist. I think he is a student. So maybe / probably he knows even better than most analists...
Offtopic:
Since my kids are not going to college on a short term (2 and 5 years old) I still expect my Jiangbo shares to generate enough profit to be able to pay for their education.
I can't believe it 5-10x more volume than other days and we have no clue why that is...
Oh well, ignorance is a bless
I admit these thoughts crossed my mind too. As farfetched as they may seem. I used numbers which differ a little. But they come down to the same conclusion. Allthough it won't happen in 2009 I guess...but my post is almost a year old.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32221471
GNPH going to $100 is that possible?
I think it is possible within one year from now:
Let's take the predicted 100 million revenues this year and add 30% growth, that makes 130 million revenues for fiscal year 2009.
Profit will be between 25-35% of that revenues, let's assume it will be 30% of 130 million. That means a profit of $ 39 million.
Assume there are 11 million shares outstanding next year (sept. '08 approx. 10.5 million). That means earnings per share 39 / 11 = $ 3.54.
If we multiply that with a PE of 30 (which is not impossible on Nasdaq for a very promising pharma company) we get an expected shareprice of $ 106.20
That means I am holding a tenbagger in my portfolio, I can't believe it !?!
Well _bbb_ sometimes I doubt even my own predictions, let alone your optimistic goal of $80.
We need good numbers, news on uplisting and news on new drugs. As long as those three things don't happen all together, we're never going to get higher than $15 or maybe $20. If none of them happen at all in the near future, I don't know where we'll be heading
So if I understand correctly: if the uplisting is announced we'll probably double from here, that makes about $20. Then we need another double (a few good new drugs could do that ?) to reach $40. And then we're there, my final goal for selling...
We'll see if it all goes that smoothly, things never have with JGBO so far ...
We can only hope the uplisting will follow soon and that it helps to keep the volume on acceptable levels. What else would?
We've "just" had a reverse split....
Good luck then!
What do you mean by real adding, thus far you've only wanted to buy cheapies, below $7 etc
Those days are over...
You can always buy my shares, you know the price...
Hope they are having a succesfull trade fair. Anyone visiting ?
You are right on that. But I was just trying to bring up a positive thing: at least short shares aren't up to 10 or 20k again like they where not so long ago.
Hopefull.
June 15th.
Short Interest 2,460
Percent Change -8.48%
Average Daily Share Volume 12,605
Short interest went down by 8%. This means that the marketmakers/shorties don't think we will go down much further.
http://www.otcbb.com/asp/OTCE_Short_Interest.asp Check for yourself.
If we keep going this way we will be back at the old level again
Six more days and FY2009 is history. Hope the numbers will hold a positive surprise.
Let's start FY 2010 with uplisting so we can get past this manipulation by marketmakers.
Something positive:
Top 3 OTC Value Plays for 2009
By Justin • on June 22, 2009
General Growth Properties, Inc. (GGWPQ), Jiangbo Pharmaceuticals, Inc. (JGBO), and Worldwide Energy and Manufacturing USA, Inc. (WEMU) are three value plays for 2009.
General Growth Properties Inc. (GGWPQ.PK: 1.85 -10.63%) may be in bankruptcy, but that’s not stopping investors from buying up the common stock. Billionaire investor Bill Ackman is one hedge fund manager who believes that the common stock will remain intact post-bankruptcy. After all, giant mall operator is only facing a short-term cash crunch, not long-term operational problems. Many experts believe that this stock could jump more than 5x if the common stock remains intact.
Jiangbo Pharmaceuticals, Inc. (JGBO.OB: 10.20 -2.86%) is one of the cheapest profitable micro-cap stocks in the markets, trading with a price-earnings ratio of 4.83x, despite strong quarterly growth. In fact, 77 percent of its market cap is backed by cold, hard cash on its books! And with low debt and continued improvements in quarterly growth, this stock is a bargain by any measure. Moreover, there’s a catalyst in that it could become a Nasdaq listed stock in the future.
Worldwide Energy and Manufacturing USA, Inc. (WEMU.OB: 4.80 +2.13%) is another cheap profitable micro-cap stock, with a price-earnings multiple of 8.6x, despite strong quarterly growth. The company’s recent entry into the U.S. solar energy market should propel shares higher, while a pending Nasdaq listing could provide a catalyst in the short-term. The company’s balance sheet is also healthy with $3.5 million in cash and very little debt.
In the end, these three stocks represent strong value plays in the OTC markets. General Growth represents a great speculative play with a lot of upside, while Jiangbo and Worldwide Energy are strong value plays that should provide stable returns that outperform the market over the long run.
Here is the link:
http://theotcinvestor.com/top-3-otc-value-plays-for-2009-301/#
Next week will be better
I hope
Have a nice weekend all
Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin
Company to Launch Promotional Campaign for Laiyang Pear Cough Syrup
LAIYANG, China, June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: JGBO - News; the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it will attend the China New Drugs Trade Fair from June 26 to 28, 2009 at Tianjin Binhai International Convention & Exhibition Center, and also plans to launch a new promotional campaign for its recently acquired Laiyang Pear Cough Syrup.
Jiangbo plans to promote its brand at the trade fair to increase the popularity of its Traditional Chinese Medicine (TCM) products. The Company will promote the portfolio of TCM products it acquired by purchasing Hongrui Pharmaceutical Company in early 2009 to its existing customers, and speak with new potential distributors.
Laiyang City is famous for its pears. "Laiyang Pear" is a trademark for place of origin which is registered with the Chinese National Industrial and Commercial Bureau. In production by Jiangbo since April of 2009, Laiyang Pear Cough Syrup is made from Laiyang Pears and is used to relieve coughs and remove phlegm arising from colds or other ailments. The Company believes that Laiyang Pear Cough Syrup tastes much better than alternative cough syrups. The cough syrup's pear taste makes it especially popular among children.
As a leading manufacturer using Laiyang Pears in a cough syrup, Jiangbo intends to leverage its location in Laiyang and extensive sales network to become the market leader for this type of cough syrup.
"We look forward to attending the trade fair. We plan to renew old contacts, and hope to develop new relationships with distributors through which we will increase our TCM sales," said Mr. Wubo Cao, CEO of Jiangbo. "Separately, we plan to start an active promotional campaign for our Laiyang Pear Cough Syrup. The current market size for cough syrups in China is approximately RMB 5 to 10 billion annually and is rapidly growing. We currently estimate that our sales of Laiyang Pear Cough Syrup in China will reach RMB 500 million within the next five years."
About the 44th China New Drugs Trade Fair
The China New Drugs Trade Fair is a professional forum for individuals and companies interested in commercializing drugs and new pharmaceutical products in China. The event will be held June 26 to 28 at the Binhai International Convention & Exhibition Center in Tianjin, China. The trade fair plays an important role in connecting "Government, industry, academic research, funding and service." More than 70,000 professionals are expected to attend the trade fair. For more information about the China New Drugs Trade Fair, please visit http://en.newdrugschina.com .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
http://www.jiangbopharma.com
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
http://www.ccgirasia.com
Here is the link:
http://finance.yahoo.com/news/Jiangbo-Pharmaceuticals-to-prnews-421395656.html?x=0&.v=67
RMB 500 million = 73 million dollar !?
Bollinger bands are pinching together. Almost a guarantee for a move in pps the coming days... bet it will take us to the next step: $13....
Strange numbers ?!
Does 13.75 provide the direction for this week?
11.65 488 OBB 13:17:20
12.00 500 OBB 12:17:05
z 13.75 500 OBB 10:42:17
11.99 496 OBB 10:41:13
11.60 1000 OBB 10:27:55
And then to think that the better part of that volume was traded in the first 1~2 hours...
in a few weeks/months we will be trading at $15~20.
Yep, I know for sure, I only have to kee my patience and then I'll be rewarded...
Nice volume, nice pps (so far)
Glen,
Are you a member of linkedin?
If so: http://www.linkedin.com/in/kuepper
Let`s get this out too, maybe it helps...
http://geoinvesting.com/companies/jgbo_jiangbo_pharmaceuticals/bargain
http://geoinvesting.com/about/InvestmentDisciplines.aspx
http://geoinvesting.com/companies/jgbo_jiangbo_pharmaceuticals/alerts
More people who think we've bought the right stock.
Nothing really new, but a nice summary:
http://theotcinvestor.com/jiangbos-restructuring-efforts-appear-to-be-paying-off-275/
Jiangbo’s Restructuring Efforts Appear to be Paying Off
By Justin • on June 8, 2009
Jiangbo Pharmaceuticals, Inc. (JGBO) posted record earnings of $8.9 million, or $0.44 per share, while retaining a robust balance sheet last quarter. Meanwhile, the pharmaceutical company reaffirmed operating income guidance of $40 to $43 million on revenues of $122 to $130 million amid a growing Chinese pharmaceuticals industry.
Jiangbo Pharmaceuticals, Inc. (JGBO.OB: 11.20 -4.68%), a U.S.-based company developing pharmaceutical products in China, began the year with a restructuring effort that could start paying big dividends. Revenues and net income figures were lower following restructuring charges, but a sharp increase in operating income and non-GAAP adjusted net income show promise.
Jiangbo’s Effective Restructuring
In January 2009, Jiangbo restructured its distribution and sales systems to concentrate on using 28 large independent regional distributors. The independent distributors agreed to take on higher direct marketing and sales expenses if they received lower unit prices for the company’s products. The predictable result is lower revenues, but less expenses and greater income.
Jiangbo’s discounts amounted to approximately 26% during their fiscal third quarter, which led to a drop in revenues. However, expenses fell 63.1% during the same period as advertising costs were shifted to the independent distributors. As a result, operating income increased 53.6% during the period, and the strategy appeared to pay off handsomely.
Despite the positive results, some investors remained concerned over Jiangbo’s net loss. However, a closer look reveals that these losses can be attributed to discontinued operations, a gain on trading securities, and amortization of debt. When these are taken out of the equation, the company reported non-GAAP adjusted net income of $10 million, or $0.97 per share.
Jiangbo’s Robust Balance Sheet
Jiangbo has also managed to keep a robust balance sheet, with $86.1 million in cash and working capital of $85.6 million. Meanwhile, current liabilities stood at just $27.4 million with convertible debt, net of $29.8 million discount, was $5.0 million. Finally, shareholder equity ended the quarter at $113.9 million, compared to $95.5 million as of June 30, 2008.
Meanwhile, strong cash flow generation of $41.4 million during the first nine months of fiscal 2009 will sustain its future working capital needs and successfully implement its growth strategies, which include the expansion of manufacturing facilities. This reduces the risks that the company will need to raise additional debt or equity capital in the near future.
Conclusions
In April 2009, the Chinese government unveiled its “Guideline of Deepening the Reform of Health Care System” – a blueprint for health care over the next decade. By 2020, the world’s most populated nation plans to have a basic health care system that can provide “safe, effective, convenient and affordable” health care services to urban and rural residents. The State Council also announced an investment of 850 billion Yuan (US$124 billion) to implement the health care reform plan in China.
In the end, Jiangbo’s restructuring plan appears to be effective in increasing operating income and should help increase revenue growth rates down the road. Meanwhile, a strong balance sheet and cash flow generation should help it preserve and increase shareholder value over the long-term. Combined with China’s rapidly growing pharmaceutical industry, this is a stock that investors may want to investigate closely over the coming months.
Oops, today's trading proves that my math was too simple
Now trading at $11.25, but the day isn't over yet...
I like to keep things simple, so even I can understand I am no professor in mathematics, so I'll do some simple calculation excercices.
Last few weeks our beloved shares have gained a dollar a share every week, if we continue to do so until the end of the year that would give us a goal of $ 30-40 by the end of this year.
I know, this might be a bit exaggerated, but who knows where we'll go. Uplisting on the way...
Good luck all.
_bbb_: you can make me assistant mod on the JGBO board, I think the ibox could need an update. We could start by making the layout a little less wild. Fix up the broken links, and place everything in the proper timeline.
But I can't help coming week because I am going on holiday. Sorry.
We have had a nice week, just like the last few weeks before. This week we opened at $10.05 and today we've closed at $10.75
More important the rise was accompanied by big volumes, also just like last weeks. So we can say 'Jiangbo has definitely found its way up.
Fiscal year 2009 has only still 1 month left. Results can be expected in Sept. 2009. Uplisting on the way. New drugs. Possible merger or acquisition (LTUS?). Share buyback: will Jiangbo buy at these levels or was that program just an ultimate support because the pps tanked so far...?
I had hoped we would have gathered more answersto to our previous questions.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37683819
Or where these questions adressed in the conference call?
I consider myself to know stuff about pc's etc. Friends and family ask me when they don't manage to get things working. But this is out of my league. With orange symbol you mean the RSS-sgn I guess?
Thanks wiedsche so far. I've tried the tip on Firefox etc. But I can't get it working. Enough for now. I guess I'll have to go cold-turkey when I am on a holiday!